FDA
-
-
-
-
-
-
-
Amylyx launches expanded access program for post-bariatric hypoglycemia drug
-
-
-
-
-
-
-
Amylyx reports early safety data for ALS drug AMX0114
-
-
-
-
-
-
-
Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results
-
-
-
-
-
-
-
Amylyx Pharmaceuticals (AMLX) Announces Positive Long-Term Results from Phase 2 HELIOS Trial of AMX0035
-
-
-
-
-
-
-
Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis
-
-
-
-
-
-
-
Leerink Partners Reiterates Market Perform Rating on Amylyx Pharmaceuticals inc. (AMLX)
-
-
-
-
-
-
-
Amylyx Pharmaceuticals Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist (Avexitide) with FDA Breakthrough Therapy Designation
-
323,981 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

